{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:00:27Z","timestamp":1791568827552,"version":"4.3.4"},"reference-count":27,"publisher":"Society of Nuclear Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.2967\/jnumed.123.266817","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T14:40:24Z","timestamp":1709217624000},"page":"573-579","source":"Crossref","is-referenced-by-count":24,"title":["Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study"],"prefix":"10.2967","volume":"65","author":[{"given":"Christopher","family":"Eigler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"McDougall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Bauman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bernhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hentschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine A.","family":"Blackham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Nicolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melpomeni","family":"Fani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Wild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Cordier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2024,2,29]]},"reference":[{"key":"2024061312401050000_65.4.573.1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0193"},{"key":"2024061312401050000_65.4.573.2","doi-asserted-by":"crossref","first-page":"e790","DOI":"10.1016\/j.wneu.2019.01.171","article-title":"Cranial nerve outcomes after surgery for frontal skull base meningiomas: the eternal quest of the maximum-safe resection with the lowest morbidity","volume":"125","author":"Schneider","year":"2019","journal-title":"World Neurosurg."},{"key":"2024061312401050000_65.4.573.3","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.3171\/2016.5.JNS152809","article-title":"Adjuvant radiotherapy for atypical meningiomas","volume":"126","author":"Bagshaw","year":"2017","journal-title":"J Neurosurg."},{"key":"2024061312401050000_65.4.573.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-3019(03)00377-X"},{"key":"2024061312401050000_65.4.573.5","first-page":"1865","article-title":"Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A","volume":"6","author":"Schulz","year":"2000","journal-title":"Clin Cancer Res."},{"key":"2024061312401050000_65.4.573.6","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-009-1115-z"},{"key":"2024061312401050000_65.4.573.7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.155853"},{"key":"2024061312401050000_65.4.573.8","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.147256"},{"key":"2024061312401050000_65.4.573.9","doi-asserted-by":"crossref","first-page":"vii85","DOI":"10.1093\/neuonc\/noac209.322","article-title":"CTN1-57. Radionuclide therapy with 177Lu-DOTATATE (Lutathera) in adults with advanced intracranial meningioma: interim analysis results of a single-arm, open-label, multicenter phase II study","volume":"24","author":"Kurz","year":"2022","journal-title":"Neuro Oncol."},{"key":"2024061312401050000_65.4.573.10","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.249607"},{"key":"2024061312401050000_65.4.573.11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.7873"},{"key":"2024061312401050000_65.4.573.12","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.3390\/jcm11092364","article-title":"The current role of peptide receptor radionuclide therapy in meningiomas","volume":"11","author":"Fodi","year":"2022","journal-title":"J Clin Med."},{"key":"2024061312401050000_65.4.573.13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0607761103"},{"key":"2024061312401050000_65.4.573.14","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.3390\/ph14121265","article-title":"Distinct in\u00a0vitro binding profile of the somatostatin receptor subtype 2 antagonist [177Lu]Lu-OPS201 compared to the agonist [177Lu]Lu-DOTA-TATE","volume":"14","author":"Mansi","year":"2021","journal-title":"Pharmaceuticals (Basel)."},{"key":"2024061312401050000_65.4.573.15","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.138834"},{"key":"2024061312401050000_65.4.573.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.211094"},{"key":"2024061312401050000_65.4.573.17","doi-asserted-by":"publisher","DOI":"10.1088\/0031-9155\/56\/8\/001"},{"key":"2024061312401050000_65.4.573.18","first-page":"7","article-title":"ICRP publication 107. Nuclear decay data for dosimetric calculations","volume":"38","author":"Eckerman","year":"2008","journal-title":"Ann ICRP."},{"key":"2024061312401050000_65.4.573.19","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noy126"},{"key":"2024061312401050000_65.4.573.20","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00259-023-06383-1","article-title":"A phase I\/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours","volume":"51","author":"Wild","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024061312401050000_65.4.573.21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1026"},{"key":"2024061312401050000_65.4.573.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427"},{"key":"2024061312401050000_65.4.573.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(01)00772-X"},{"key":"2024061312401050000_65.4.573.24","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.3390\/cancers14051172","article-title":"Radiolabeled somatostatin analogs: a continuously evolving class of radiopharmaceuticals","volume":"14","author":"Fani","year":"2022","journal-title":"Cancers (Basel)."},{"key":"2024061312401050000_65.4.573.25","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265484"},{"key":"2024061312401050000_65.4.573.26","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.191684"},{"key":"2024061312401050000_65.4.573.27","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-7-99"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.123.266817","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T15:43:27Z","timestamp":1718293407000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.123.266817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,1]]},"published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.2967\/jnumed.123.266817"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.123.266817","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,29]]}}}